期刊
CLINICAL CANCER RESEARCH
卷 21, 期 22, 页码 4996-4998出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-15-1214
关键词
-
类别
资金
- NCI NIH HHS [R21 CA178450, R21 CA185536, L30CA136381, L30 CA136381, K12 CA088084, R21CA178450] Funding Source: Medline
C-13-pyruvate hyperpolarized magnetic resonance imaging (HP-MRI) is emerging as a viable quantitative biomarker for solid tumor response and normal tissue toxicity after radiotherapy. This technology effectively predicts response related to metabolic agents or alterations in the tumor microenvironment, but challenges remain to be addressed to ensure successful translational implementation. (C) 2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据